All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

Venetoclax + Azacitidine

28%

ARA-C + Ida/daunorubicin

71%

L-PAM, pred + bortezomib

0%

7 votes

The AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

How would you treat newly diagnosed induction-eligible patients with acute myeloid leukemia?

Fathi highlights that to determine eligibility for intensive cytotoxic chemotherapy, patient's fitness, comorbidities, and functional status are considered. He outlines induction chemotherapy regimens and highlights the two step approach to newly diagnosed AML; intensive chemotherapy, followed by consolidation. Finally, Fathi explains that for less robust patients a gentler regimen including hypomethylating agents or BCL2 inhibitors can be used as an alternative.


Share: